Literature DB >> 18081904

Intravitreal bevacizumab for vitreous haemorrhage.

Jost B Jonas, Teodosio Libondi, Stefan von Baltz, Urs Vossmerbaeumer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18081904     DOI： 10.1111/j.1600-0420.2007.01107.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  4 in total

Review 1.  A review of anti-VEGF agents for proliferative diabetic retinopathy.

Authors:  P Osaadon; X J Fagan; T Lifshitz; J Levy
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

2.  Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.

Authors:  Frank S Ong; Jane Z Kuo; Wei-Chi Wu; Ching-Yu Cheng; Wendell-Lamar B Blackwell; Brian L Taylor; Wayne W Grody; Jerome I Rotter; Chi-Chun Lai; Tien Y Wong
Journal:  J Pers Med       Date:  2013

3.  Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment.

Authors:  Reyin Lien; Mu-Hsien Yu; Kuang-Hung Hsu; Pei-Ju Liao; Yen-Po Chen; Chi-Chun Lai; Wei-Chi Wu
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

4.  Intravitreal bevacizumab improves the clearance of vitreous haemorrhage and visual outcomes in patients with proliferative diabetic retinopathy.

Authors:  Joonas Wirkkala; Risto Bloigu; Nina Maria Hautala
Journal:  BMJ Open Ophthalmol       Date:  2019-12-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.